Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JPMA Urges Drug Makers To Establish Pandemic Guidelines Amid Flu Infections

This article was originally published in PharmAsia News

Executive Summary

Japan Pharmaceutical Manufacturers Association is urging member companies to establish flu pandemic guidelines. The drug makers' trade association found that out of 60 member companies that responded to a recent survey, 40 have established such guidelines, and JPMA urged quick action for the remaining companies. The recent domestic flu infections in Japan has prompted many drug companies to take measures such as reducing sales visits to hospitals. (Click here for more - Japanese language

You may also be interested in...



US FDA Requests Ranitidine Removal But Also Encourages Research For Stable Formulations

FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.

Takeda Gets New India Chief, Mandate To Broaden Access

Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.

US FDA Exploring Virtual Advisory Cmtes.; Might Sponsors Want To Wait For In-Person Meetings?

Likelihood of webcast-only advisory committee meetings may depend on the extent of the coronavirus outbreak, Office of New Drugs Director Peter Stein tells the Pink Sheet in an interview.

UsernamePublicRestriction

Register

SC072145

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel